Rivoceranib Uses, Dosage, Side Effects and more
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
| Attribute | Details |
|---|---|
| Trade Name | Rivoceranib |
| Generic | Rivoceranib |
| Rivoceranib Other Names | APATINIB, Rivoceranib |
| Type | |
| Formula | C24H23N5O |
| Weight | Average: 397.482 Monoisotopic: 397.190260381 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
